Q2 2025 Earnings Call Transcript August 1, 2025 Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.05, ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Starting in the mid-2010s, the University of Oxford pediatrician and immunologist began working with scientists in the South African province of KwaZulu-Natal, with the aim of tracking several hundred ...

If successful, the access model for sickle cell disease gene therapies could serve as a blueprint for other such treatments ...

These 10 stocks could mint the next wave of millionaires › Ocugen (NASDAQ:OCGN), a biotechnology company developing gene therapies and regenerative medicine solutions for eye diseases, released its ...

Ixo-vec reduced anti-VEGF injection frequency and was well tolerated in patients with wet AMD. A phase 3 pivotal trial ...

Daniel Cressy will be the first patient in Louisiana to complete the gene therapy treatment for sickle cell disease.

The primary safety risks associated with gene therapy include immune reactions and off-target effects in unintended organs, such as the liver, lungs, and spleen. Nevertheless, Ali and Townsend note ...

Gain insights from Ocugen's Q2 2025 earnings call, highlighting clinical advancements, strategic partnerships, BLA milestones for 2026-2027, and ...

Targeted rewriting of the epigenome promises to overcome several challenges in direct gene editing in patient therapies.

Parents of boys with Duchenne muscular dystrophy weigh in on drug innovation and medical regulation.

Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...